Trabectedin for the Treatment of Advanced Soft Tissue Sarcoma (TA185)

Technology Appraisal Guidance No. 185

Source: National Institute for Health and Care Excellence

1. Guidance

1.1  Trabectedin is recommended as a treatment option for people with advanced soft tissue sarcoma if:

  • treatment with anthracyclines and ifosfamide has failed or
  • they are intolerant of or have contraindications for treatment with anthracyclines and ifosfamide

and

  • the acquisition cost of trabectedin for treatment needed after the fifth cycle is met by the manufacturer.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

An abridged version of this guidance (a 'quick reference guide') is also available. Printed copies of the quick reference guide can be obtained by ing 0845 003 7783 or emailing [email protected] and quoting reference number N2104. It is also available on the Internet at

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: [email protected]

Trabectedin for the treatment of advanced soft tissue sarcoma
Issue Date: February 2010
Review Date: February 2013


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

New secondary prevention approach backed for patients with stable cardiovascular disease

New secondary prevention approach backed for patients with stable cardiovascular disease

NHS prescribers have a new routine option for preventing...

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Ranitidine in short supply after contamination fears prompt precautionary recall

Ranitidine in short supply after contamination fears prompt precautionary recall

GPs have reported shortages of ranitidine following...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Alzhok and ranitidine oral soln.
Use our...